A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
复制标题
DOI：
10.1007/s11934-019-0866-8
复制
发表时间：
2019-01-01
影响因子：
2.6
通讯作者：
Lopez, Jose I.
中科院分区：
文献类型：
--
作者：
Nunes-Xavier, Caroline E.;Angulo, Javier C.;Lopez, Jose I.
综述目的靶向PD-1/PD-L1免疫检查点是局部晚期和转移性肾透明细胞癌（CCRCC）患者的一种新治疗工具。本次审查的目的是为临床医生提供一个最新的翻译洞察到目前的状态的一种治疗方法，可能会影响显着patient's life.Recent Findings免疫检查点抑制最近表现出有前途的结果，在选定的CCRCC患者的肿瘤进展和生存。用免疫检查点抑制剂（ICI）治疗这些患者的决定依赖于肿瘤中炎性细胞中PD-1/PD-L1阳性的免疫组织化学检测，这使得病理学家的作用至关重要，但临床上对使用免疫组织化学（IHC）预测治疗反应的可靠性的关注正在增加。从基础科学及其基本原理到临床常规中的日常应用。
Purpose of Review Targeting PD-1/PD-L1 immune checkpoints is a new therapeutic tool in patients with locally advanced and metastatic clear cell renal cell carcinoma (CCRCC). The purpose of this review is to offer clinicians an updated translational insight into the current status of a therapeutic alternative that may impact significantly patient's life.Recent Findings Immune checkpoint inhibition has recently demonstrated promising results in selected CCRCC patients with respect to tumor progression and survival. The decision to treat these patients with immune checkpoint inhibitors (ICI) relies on the immunohistochemical detection of PD-1/PD-L1 positivity in inflammatory cells in the tumor, which makes the role of the pathologist crucial, but clinical concern upon the reliability to use immunohistochemistry (IHC) to predict therapeutic response is increasing.Summary We review the state of the art of the immune checkpoint inhibition in CCRCC, from the basic science and its fundamentals to the daily application in clinical routine.